Abstract
Angiogenesis has an essential role in many important pathological and physiological settings. It has been shown that vascular permeability factor/vascular endothelial growth factor (VPF/VEGF), a potent cytokine expressed by most malignant tumors, has critical roles in vasculogenesis and both physiological and pathological angiogenesis. We report here that at non-toxic levels, the neurotransmitter dopamine strongly and selectively inhibited the vascular permeabilizing and angiogenic activities of VPF/VEGF. Dopamine acted through D2 dopamine receptors to induce endocytosis of VEGF receptor 2, which is critical for promoting angiogenesis, thereby preventing VPF/VEGF binding, receptor phosphorylation and subsequent signaling steps. The action of dopamine was specific for VPF/VEGF and did not affect other mediators of microvascular permeability or endothelial-cell proliferation or migration. These results reveal a new link between the nervous system and angiogenesis and indicate that dopamine and other D2 receptors, already in clinical use for other purposes, might have value in anti-angiogenesis therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Graybiel, A.M., Hirsch, E.C. & Agid, Y. The nigrostriatal system in Parkinson's disease. Adv. Neurol. 53, 17–29 (1990).
Goldstein, M. & Deutch, A.Y. Dopaminergic mechanisms in the pathogenesis of schizophrenia. FASEB J. 6, 2413–2421 (1992).
Olanow, C.W. & Tatton, W.G. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22, 123–144 (1999).
Egan, M.F. & Weinberger, D.R. Neurobiology of schizophrenia. Curr. Opin. Neurobiol. 7, 701–707 (1997).
Wick, M.M. Dopamine: a novel antitumor agent active against B-16 melanoma in vivo. J. Invest. Dermatol. 71, 163–164 (1978).
Wick, M.M. 3,4-Dihydroxybenzylamine: a dopamine analog with enhanced antitumor activity against B16 melanoma. J. Natl. Cancer Inst. 63, 1465–1467 (1979).
Wick, M.M. Levodopa and dopamine analogs: melanin precursors as antitumor agents in experimental human and murine leukemia. Cancer Treat. Rep. 63, 991–997 (1979).
Wick, M.M. Levodopa and dopamine analogs as DNA polymerase inhibitors and antitumor agents in human melanoma. Cancer Res. 40, 1414–1418 (1980).
Wick, M.M. Levodopa and dopamine analogs: dihydroxy and trihydroxybenzylamines as novel quinol antitumor agents in experimental leukemia in vivo. Cancer Treat. Rep. 65, 861–867 (1981).
Wick, M.M. & Mui, A. Synthesis and biologic evaluation of the dopamine analog N- acetyldopamine in experimental leukemia in mice. J. Natl. Cancer Inst. 66, 351–354 (1981).
Dasgupta, P.S. & Lahiri, T. Antitumor effect of i.p. dopamine in mice bearing Ehrlich ascites carcinoma. J. Cancer Res. Clin. Oncol. 113, 363–368 (1987).
Basu, S. & Dasgupta, P.S. Role of dopamine in malignant tumor growth. Endocrine 12, 237–241 (2000).
Basu, S. & Dasgupta, P.S. Dopamine, a neurotransmitter, influences the immune system. J. Neuroimmunol. 102, 113–124 (2000).
Ricci, A., Collier, W.L. & Amenta, F. Pharmacological characterization and autoradiographic localization of dopamine receptors in the portal vein. J. Auton. Pharmacol. 14, 61–68 (1994).
Bacic, F., Uematsu, S., McCarron, R.M. & Spatz, M. Dopaminergic receptors linked to adenylate cyclase in human cerebromicrovascular endothelium. J. Neurochem. 57, 1774–1780 (1991).
Brown, L. et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. in Regulation of Angiogenesis (eds. Goldberg, I. & Rosen, E.) (Birkhauser, Basel, Switzerland, 1997).
Dvorak, H.F., Nagy, J.A., Feng, D., Brown, L.F. & Dvorak, A.M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 237, 97–132 (1999).
Nagy, J. et al. Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling and stroma formation in the peritoneal lining. Cancer Res. 55, 376–385 (1995).
Nagy, J.A., Meyers, M.S., Masse, E.M., Herzberg, K.T. & Dvorak, H.F. Pathogenesis of ascites tumor growth: fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity. Cancer Res. 55, 369–375 (1995).
Nagy, J.A. et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability and ascites fluid accumulation. Cancer Res. 55, 360–368 (1995).
Zaroslinski, J.F. et al. The pharmacology and subacute toxicology of dopamine. Proc. R. Soc. Med. 70, 2–6 (1977).
Dvorak, H.F. et al. Induction of a fibrin-gel investment: An early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J. Immunol. 122, 166–174 (1979).
Senger, D.R. et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983–985 (1983).
Murohara, T. et al. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 97, 99–107 (1998).
Pettersson, A. et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab. Invest. 80, 99–115 (2000).
Ferrara, N. Vascular endothelial growth factor: molecular and biological aspects. Curr. Top. Microbiol. Immunol. 237, 1–30 (1999).
Ewing, A.G., Bigelow, J.C. & Wightman, R.M. Direct in vivo monitoring of dopamine released from two striatal compartments in the rat. Science 221, 169–171 (1983).
Heeg, K., Reimann, J., Kabelitz, D., Hardt, C. & Wagner, H. A rapid colorimetric assay for the determination of IL-2-producing helper T cell frequencies. J. Immunol. Methods 77, 237–246 (1985).
Turner, H.E. et al. Angiogenesis in pituitary adenomas—relationship to endocrine function, treatment and outcome. J. Endocrinol. 165, 475–481 (2000).
Takechi, A. Effect of angiogenesis inhibitor TNP-470 on vascular formation in pituitary tumors induced by estrogen in rats. Neurol. Med. Chir. 34, 729–733 (1994).
Nagai, Y. et al. Plasma levels of vascular endothelial growth factor in patients with acromegaly. Horm. Metab. Res. 32, 326–329 (2000).
Berkman, R.A., & Oldfield, R.H. Expression of vascular permeability factor / vascular endothelial growth factor gene in central nervous system neoplasms. J. Clin. Invest. 91, 153–159 (1993).
Otsuka, F. et al. Quantitative analysis of growth - related factors in human pituitary adenomas. Lowered insulin-like growth factor-I and its receptor mRNA in growth hormone-producing adenomas. Regul. Pept. 83, 31–38 (1999).
Heaney, A.P., Horwitz, G.A., Wang, Z., Singson, R. & Melmed, S. Early involvement of estrogen induced pituitary transforming gene and fibroblast growth expression in prolactinoma pathogenesis. Nature Med. 5, 1317–1321 (1999).
Ashraf, S. et al. Blood vessels in liver metastasis from both sarcoma and carcinoma lack perivascular innervation and smooth muscle cells. Clin. Exp. Metastasis. 15, 484–498 (1997).
Chamary, V.L., Robson, T., Loizidou, M., Boulos, P.B. & Burnstock, G. Progressive loss of perivascular nerves adjacent to colorectal cancer. Eur. J. Surg. Oncol. 26, 588–593 (2000).
Pereira da Silva, J.A., & Carmo-Fonseca, M. Peptide containing nerves in human synovium: immunohistochemical evidence for decreased innervation in rheumatoid arthritis. J. Rheumatol. 17, 1592–1599 (1990).
Miller, L.E., Justen, H.P., Scholmerich, J. & Straub, R.H. The loss of sympathetic nerve fibres in the synovial tissue of patients is accompanied by increased norepinephrine release from synovial macrophages. FASEB J. 14, 2097–2107 (2000).
Basu, S. & Dasgupta, P.S. Decreased dopamine receptor expression and its second-messenger cAMP in malignant human colon tissue. Dig. Dis. Sci. 44, 916–921 (1999).
Braunwald, E. Evolution of the management of acute myocardial infarction: a 20th century saga. Lancet 352, 1771–1774 (1998).
Katzung, B. (ed.) Basic and Clinical Pharmacology. (Appleton and Lange, Stamford, Connecticut, 1998).
Acknowledgements
We thank D.R. Senger and J. Lawler for their comments and criticisms and K. Datta for technical help. This work was partly supported by NIH grants to D.M., and H.F.D., by the Massachusetts Department of Public Health, by the Department of Defense to D.M., and under terms of a contract from the National Foundation for Cancer Research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Basu, S., Nagy, J., Pal, S. et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 7, 569–574 (2001). https://doi.org/10.1038/87895
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/87895
This article is cited by
-
Impaired cerebral microvascular endothelial cells integrity due to elevated dopamine in myasthenic model
Journal of Neuroinflammation (2024)
-
Interventions to prevent or reduce the incidence and severity of ovarian hyperstimulation syndrome: a systematic umbrella review of the best clinical evidence
Reproductive Biology and Endocrinology (2023)
-
BH4 supplementation reduces retinal cell death in ischaemic retinopathy
Scientific Reports (2023)
-
Dopamine receptors gene overexpression in the microenvironment of invasive gastric cancer and its potential implications
Molecular Biology Reports (2023)
-
Nerves in gastrointestinal cancer: from mechanism to modulations
Nature Reviews Gastroenterology & Hepatology (2022)